Newly Published Patent Applications | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3175 of 3186  at  6/30/2020 4:53:24 AM  by


The following message was updated on 7/3/2020 2:00:38 AM.

Newly Published Patent Applications

1) WO2020132171 (A1) Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors - International App

2) US2020197411 (A1) Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators

3) US2020197372 (A1)
Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound

4) US2020197381 (A1) Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent

Patent App 1 relates to creating better imaging and treatment of subtypes found within GI tract, Adrenal and Pancreatic cancers. Relacorilant is used with somatostatin analogs (e.g. Signifor, octreotide) to help image tumors with poor somatostatin expression. This expression provides better imaging.

Patent 2 refers to relacorilant’s (and other GR drugs’) ability to restore regular clotting. This is accomplished by normalizing Factor VIII & VWF, and thrombin-antithrombin levels.

With excess clotting, Cushing’s patients have higher risks for stroke, thrombosis, and fatality. Medical therapy with Korlym competitors including Signifor, ketoconazole, and cabergoline appear ineffective. On the other hand, relacorilant appears to normalize Factor VIII levels.

Patent App 3 extends relacorilant’s IP to certain softgel capsule formulations

Patent App 4 is about a personalized medicine method in which cancer patients are:
a) Assessed baseline expression of certain genes (found amenable to GR drug treatment);
b) Then given a GR drug (e.g. relacorilant or exicorilant) + chemotherapy (e.g. Abraxane);
c) and then assessed for changes from the gene expression baselines.

Corcept is seeking to protect the typical approach to personalized cancer treatment with GR drugs involving designated genes. 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 8     Views: 122
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by